Benign Prostatic Hyperplasia Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update

The Benign Prostatic Hyperplasia clinical trial market research report provides an overview of the Benign Prostatic Hyperplasia clinical trials scenario. The report provides top-line data relating to the clinical trials on Benign Prostatic Hyperplasia. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.

Benign Prostatic Hyperplasia Clinical Trials Market Segmentation by Regions and Countries

The key regions in the Benign Prostatic Hyperplasia clinical trials market are Asia-Pacific, Europe, North America, Middle East & Africa, and South & Central America, among others. Asia-Pacific dominates the market.

In a country-wise analysis, as of November 2022, China has the highest number of Benign Prostatic Hyperplasia clinical trials, followed by South Korea, Japan, the US, India, Iran, Russia, Germany, Italy, and Canada. 

G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Japan has the highest proportion of Benign Prostatic Hyperplasia to Male Health clinical trials as of November 2022. Moreover, the majority of the clinical trials were conducted in Japan.

E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia has the highest proportion of Benign Prostatic Hyperplasia to Male Health clinical trials as of November 2022. Out of all the clinical trials conducted in the E7 countries, the majority were in China.

Benign Prostatic Hyperplasia Clinical Trials Analysis by Regions

For more regional insights into the Benign Prostatic Hyperplasia clinical trials market, download a free report sample

Benign Prostatic Hyperplasia Clinical Trials Market Segmentation by Sponsor Types

The key sponsor types in the Benign Prostatic Hyperplasia clinical trials market are institution, company, and the government. Out of them, company dominates the market.

Benign Prostatic Hyperplasia Clinical Trials Market Analysis by Sponsor Types

For more sponsor type insights into the Benign Prostatic Hyperplasia clinical trials market, download a free report sample

Benign Prostatic Hyperplasia Clinical Trials Market - Competitive Landscape

The leading sponsors in the Benign Prostatic Hyperplasia clinical trials market are GSK plc, Mayne Pharma Group Ltd, Kissei Pharmaceutical Co Ltd, Astellas Pharma Inc, Fimei SpA, Eli Lilly and Co, C. H. Boehringer Sohn AG & Co KG, Glanbia Nutritionals Inc, Teva Pharmaceutical Industries Ltd, and Sanofi. Out of them, GSK plc has conducted the highest number of Benign Prostatic Hyperplasia clinical trials.

Benign Prostatic Hyperplasia Clinical Trials Market Analysis by Sponsors

To know more about the leading players in the Benign Prostatic Hyperplasia clinical trials market, download a free report sample

Benign Prostatic Hyperplasia Clinical Trials Market Report Overview

Scope

• The report provides a snapshot of the global clinical trials landscape
• The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status
• The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company
• The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for unaccomplishment
• The report provides enrollment trends for the past five years
• The report provides the latest news for the past three months

Reasons to Buy

• Assists in formulating key business strategies with regard to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in the global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional, and country level